Despite the Downward Trend in Earnings at Xilong Scientific (SZSE:002584) the Stock Spikes 48%, Bringing Five-year Gains to 93%
Despite the Downward Trend in Earnings at Xilong Scientific (SZSE:002584) the Stock Spikes 48%, Bringing Five-year Gains to 93%
Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the Xilong Scientific Co., Ltd. (SZSE:002584) share price is up 93% in the last 5 years, clearly besting the market return of around 37% (ignoring dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 74%.
選股者通常在尋找表現優於大盤的股票。儘管主動選股涉及風險(需要多元化),但它也可以提供超額回報。例如,西隆科學有限公司(SZSE:002584)的股價在過去5年中上漲了93%,顯然超過了約37%的市場回報率(不包括股息)。另一方面,最近的漲幅並不那麼令人印象深刻,股東僅上漲了74%。
Since it's been a strong week for Xilong Scientific shareholders, let's have a look at trend of the longer term fundamentals.
由於對於Xilong Scientific的股東來說,這是表現強勁的一週,讓我們來看看長期基本面的走勢。
View our latest analysis for Xilong Scientific
查看我們對希隆科學的最新分析
Given that Xilong Scientific only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.
鑑於Xilong Scientific在過去十二個月中僅獲得最低收益,我們將重點關注收入來衡量其業務發展。一般而言,我們認爲這種公司更能與虧損股票相提並論,因爲實際利潤太低了。爲了讓股東有信心公司大幅增加利潤,它必須增加收入。
In the last 5 years Xilong Scientific saw its revenue grow at 15% per year. That's well above most pre-profit companies. While the compound gain of 14% per year is good, it's not unreasonable given the strong revenue growth. If you think there could be more growth to come, now might be the time to take a close look at Xilong Scientific. Opportunity lies where the market hasn't fully priced growth in the underlying business.
在過去的5年中,希隆科學的收入以每年15%的速度增長。這遠高於大多數預盈利公司。儘管每年14%的複合收益不錯,但鑑於強勁的收入增長,這並非沒有道理。如果你認爲未來可能會有更多的增長,那麼現在可能是仔細研究西隆科學的時候了。機會在於市場尚未對標的業務增長進行全面定價的地方。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
您可以在下圖中看到收入和收入隨時間推移而發生的變化(點擊圖表查看確切值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231121/0-3fcaa4f48a9128055f78828ab97c5097-0-dab1d179a2465f27f95589e2b54cbfa0.png/big)
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. It might be well worthwhile taking a look at our free report on Xilong Scientific's earnings, revenue and cash flow.
我們很高興地向大家報告,首席執行官的薪酬比資本狀況相似的公司的大多數首席執行官更適中。始終值得關注首席執行官的薪酬,但更重要的問題是公司多年來是否會增加收益。我們關於Xilong Scientific的收益、收入和現金流的免費報告可能值得一看。
A Different Perspective
不同的視角
It's good to see that Xilong Scientific has rewarded shareholders with a total shareholder return of 74% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 14% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Xilong Scientific (at least 1 which is significant) , and understanding them should be part of your investment process.
很高興看到希隆科學在過去十二個月中向股東提供了74%的股東總回報率。由於一年期股東總回報率好於五年期股東總回報率(後者爲每年14%),該股的表現似乎在最近有所改善。鑑於股價勢頭仍然強勁,可能值得仔細研究該股,以免錯過機會。我發現從長遠來看,將股價視爲業務表現的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,以永遠存在的投資風險幽靈爲例。我們已經確定了希隆科學的三個警告信號(至少有一個很重要),了解它們應該成爲您投資過程的一部分。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。